GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Tianjin TEDA Biomedical Engineering Co Ltd (HKSE:08189) » Definitions » Piotroski F-Score

Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Piotroski F-Score : 6 (As of Jun. 06, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Tianjin TEDA Biomedical Engineering Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tianjin TEDA Biomedical Engineering Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score or its related term are showing as below:

HKSE:08189' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 6
Current: 6

During the past 13 years, the highest Piotroski F-Score of Tianjin TEDA Biomedical Engineering Co was 6. The lowest was 2. And the median was 5.


Tianjin TEDA Biomedical Engineering Co Piotroski F-Score Historical Data

The historical data trend for Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin TEDA Biomedical Engineering Co Piotroski F-Score Chart

Tianjin TEDA Biomedical Engineering Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 4.00 4.00 6.00

Tianjin TEDA Biomedical Engineering Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 - - - 6.00

Competitive Comparison of Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score

For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was HK$-22.1 Mil.
Cash Flow from Operations was HK$-14.4 Mil.
Revenue was HK$435.3 Mil.
Gross Profit was HK$23.4 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (376.552 + 331.719) / 2 = HK$354.1355 Mil.
Total Assets at the begining of this year (Dec22) was HK$376.6 Mil.
Long-Term Debt & Capital Lease Obligation was HK$22.2 Mil.
Total Current Assets was HK$208.2 Mil.
Total Current Liabilities was HK$237.2 Mil.
Net Income was HK$-30.7 Mil.

Revenue was HK$450.9 Mil.
Gross Profit was HK$16.6 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (425.619 + 376.552) / 2 = HK$401.0855 Mil.
Total Assets at the begining of last year (Dec21) was HK$425.6 Mil.
Long-Term Debt & Capital Lease Obligation was HK$39.3 Mil.
Total Current Assets was HK$215.6 Mil.
Total Current Liabilities was HK$243.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tianjin TEDA Biomedical Engineering Co's current Net Income (TTM) was -22.1. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tianjin TEDA Biomedical Engineering Co's current Cash Flow from Operations (TTM) was -14.4. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-22.051/376.552
=-0.05856031

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-30.656/425.619
=-0.07202686

Tianjin TEDA Biomedical Engineering Co's return on assets of this year was -0.05856031. Tianjin TEDA Biomedical Engineering Co's return on assets of last year was -0.07202686. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Tianjin TEDA Biomedical Engineering Co's current Net Income (TTM) was -22.1. Tianjin TEDA Biomedical Engineering Co's current Cash Flow from Operations (TTM) was -14.4. ==> -14.4 > -22.1 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=22.198/354.1355
=0.06268222

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=39.346/401.0855
=0.09809878

Tianjin TEDA Biomedical Engineering Co's gearing of this year was 0.06268222. Tianjin TEDA Biomedical Engineering Co's gearing of last year was 0.09809878. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=208.192/237.177
=0.87779169

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=215.61/243.722
=0.88465547

Tianjin TEDA Biomedical Engineering Co's current ratio of this year was 0.87779169. Tianjin TEDA Biomedical Engineering Co's current ratio of last year was 0.88465547. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Tianjin TEDA Biomedical Engineering Co's number of shares in issue this year was 1894.5. Tianjin TEDA Biomedical Engineering Co's number of shares in issue last year was 1894.5. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=23.37/435.322
=0.0536844

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=16.552/450.85
=0.03671288

Tianjin TEDA Biomedical Engineering Co's gross margin of this year was 0.0536844. Tianjin TEDA Biomedical Engineering Co's gross margin of last year was 0.03671288. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=435.322/376.552
=1.15607406

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=450.85/425.619
=1.05928072

Tianjin TEDA Biomedical Engineering Co's asset turnover of this year was 1.15607406. Tianjin TEDA Biomedical Engineering Co's asset turnover of last year was 1.05928072. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+1+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tianjin TEDA Biomedical Engineering Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Tianjin TEDA Biomedical Engineering Co  (HKSE:08189) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Tianjin TEDA Biomedical Engineering Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Tianjin TEDA Biomedical Engineering Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Business Description

Traded in Other Exchanges
N/A
Address
No. 80, The 4th Avenue, 9th Floor, Block A2, Tianda Hi-Tech Park, TEDA Tianjin, Tianjin, CHN
Tianjin TEDA Biomedical Engineering Co Ltd is engaged in the research, development, and commercialization of biological compound fertilizers, medical and health products. It operates in two segments namely manufacturing and selling biological compound fertilizers and providing elderly care and health care services. The People's Republic of China is a primary geographical market for the company.
Executives
Long Ortiz 2101 Beneficial owner

Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Headlines

No Headlines